Abstract
Subcutaneous implantable defibrillators (S-ICD) are attractive for preventing sudden cardiac death in patients with hypertrophic cardiomyopathy (HCM) as they mitigate risks of transvenous leads, although they may increase the risk of inappropriate shock (IAS). We retrospectively collected data on
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
